Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 12.6%

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 572,000 shares, a drop of 12.6% from the September 30th total of 654,300 shares. Based on an average daily volume of 387,000 shares, the days-to-cover ratio is presently 1.5 days. Approximately 2.4% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Several research firms recently commented on GANX. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Wednesday, October 9th. Oppenheimer reissued an "outperform" rating and issued a $8.00 price objective on shares of Gain Therapeutics in a report on Wednesday, August 14th. Finally, Chardan Capital reissued a "buy" rating and issued a $6.00 price objective on shares of Gain Therapeutics in a report on Friday, August 9th.

Insider Transactions at Gain Therapeutics

In other news, Chairman Khalid Islam acquired 50,000 shares of Gain Therapeutics stock in a transaction dated Friday, August 9th. The stock was purchased at an average cost of $1.00 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chairman now directly owns 50,000 shares in the company, valued at $50,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.70% of the company's stock.

Institutional Trading of Gain Therapeutics

Institutional investors have recently made changes to their positions in the company. Warberg Asset Management LLC acquired a new stake in shares of Gain Therapeutics in the second quarter worth approximately $66,000. Renaissance Technologies LLC lifted its position in Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company's stock worth $152,000 after buying an additional 72,000 shares in the last quarter. Finally, Hohimer Wealth Management LLC purchased a new position in Gain Therapeutics during the second quarter worth approximately $422,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Price Performance

GANX traded down $0.08 during trading on Tuesday, hitting $2.57. The company's stock had a trading volume of 359,186 shares, compared to its average volume of 266,508. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.03. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $5.33. The business's fifty day simple moving average is $1.78 and its 200 day simple moving average is $1.85. The firm has a market capitalization of $65.61 million, a price-to-earnings ratio of -1.98 and a beta of 0.42.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.11). On average, equities research analysts forecast that Gain Therapeutics will post -1.05 EPS for the current fiscal year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.